[The treatment of the pseudocroup syndrome (author's transl)].
The results of the implementation of Myoscain E/Holzinger in the treatment of the "pseudocroup syndrome" (laryngitis catarrhalis) are reported. The generally prompt action of the drug is stressed. It is pointed out that non-response to the compound suggests a more serious form of the disease necessitating close observation. A list of diseases involved in the differential diagnosis is added.
D002648:Child; D002675:Child, Preschool; D003937:Diagnosis, Differential; D004341:Drug Evaluation; D006140:Guaifenesin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007826:Laryngismus / Q000188:drug therapy; D007827:Laryngitis / Q000175:diagnosis / Q000188:drug therapy*; D012131:Respiratory Insufficiency / Q000188:drug therapy; D013577:Syndrome; D014136:Tracheitis / Q000188:drug therapy
D006140:Guaifenesin
Zur Behandlung des Pseudokrupp-Syndromes